Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 12/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.78 |
| ▸ | MLNR | O43193 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.74 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.74 |
| ▸ | CNR1 | P21554 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | HRH2 | P25021 | 1/20 | 0.74 |
| ▸ | HTR2C | P28335 | 1/20 | 0.74 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71573 | 1.00 | PRMT1 (0.82) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL13660355 | 1.00 | PRMT1 (0.82) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL13628951 | 1.00 | PRMT1 (0.82) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL14124681 | 0.99 | PRMT1 (0.84) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL13905973 | 0.99 | PRMT1 (0.84) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL13528718 | 0.99 | PRMT1 (0.84) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL821483 | 0.96 | PRMT1 (0.90) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL14262459 | 0.96 | PRMT1 (0.90) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL13813716 | 0.95 | PRMT1 (0.91) | PRMT1BLMMLNRNR1I2PGR | |
| SCHEMBL13528730 | 0.95 | PRMT1 (0.91) | PRMT1BLMMLNRNR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280064-A1 | TRANSDERMAL DELIVERY OF OPTICAL, SPECT, MULTIMODAL, DRUG OR BIOLOGICAL CARGO LADEN NANOPARTICLE(S) IN SMALL ANIMALS OR HUMANS | CARESTREAM HEALTH, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090180964-A1 | TRANSMUCOSAL DELIVERY OF OPTICAL, SPECT, MULTIMODAL,DRUG OR BIOLOGICAL CARGO LADEN NANOPARTICLE(S) IN SMALL ANIMALS OR HUMANS | QUANTUM MEDICAL HOLDINGS, LLC | 2009-07-16 | — | — | US | disclosed |
| US-20090093700-A1 | APPARATUS AND METHOD FOR MULTI-MODAL IMAGING USING NANOPARTICLE MULTI-MODAL IMAGING PROBES | CARESTREAM HEALTH, INC. | 2009-04-09 | — | — | US | disclosed |
| US-20090086908-A1 | APPARATUS AND METHOD FOR MULTI-MODAL IMAGING USING NANOPARTICLE MULTI-MODAL IMAGING PROBES | CARESTREAM HEALTH, INC. | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090180964-A1 | TRANSMUCOSAL DELIVERY OF OPTICAL, SPECT, MULTIMODAL,DRUG OR BIOLOGICAL CARGO LADEN NANOPARTICLE(S) IN SMALL ANIMALS OR HUMANS | FABP2, PIGS, SLC35A1 | PRMT1 4518/4885BLM 4139/4885MLNR 49/4885 |
| US-20090280064-A1 | TRANSDERMAL DELIVERY OF OPTICAL, SPECT, MULTIMODAL, DRUG OR BIOLOGICAL CARGO LADEN NANOPARTICLE(S) IN SMALL ANIMALS OR HUMANS | PIGS, CUTA, CD68 | PRMT1 4718/4885BLM 3469/4885MLNR 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.